Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Eyetech Pharmaceuticals
With
Pfizer
Age
50–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Best corrected visual acuity in the study eye between 20/40 and 20/320.
Subfoveal choroidal neovascularization, secondary to age related macular degeneration, with a total lesion size \[including blood, scar/atrophy \& neovascularization\] of \< 12 total disc areas, of which at least 50% must be active CNV.
Any subretinal hemorrhage must comprise no more than 50% of total lesion size.
General Criteria:
Patients of either gender, aged greater than 50 years.
Women must be using two forms of effective contraception, or be post-menopausal for at least 12 months prior to study entry, or surgically sterile. If of child-bearing potential, a serum pregnancy test must be performed within 48 hours prior to treatment and the result made available prior to treatment initiation. The two forms of effective contraception must be implemented during the study and for at least 60 days following the last dose of test medication.
Written informed consent.
You may not be if
Any subfoveal scarring or atrophy and no more than 25% of the total lesion size may be made up of scarring or atrophy.
Patients who are eligible for PDT with Visudyne
Patients who are eligible for any other of the Sponsor's ongoing AMD studies still open to enrollment.
